News

As a result, Incyte will receive a milestone payment of $35m from Lilly related to the NDA submission. If baricitinib is granted U.S. regulatory approval, Incyte will receive

Biotie is primarily focused on developing therapeutics for central nervous system disorders. The company develops products for neurodegenerative and psychiatric disorders such as Parkinson’s disease, Alzheimer’s disease and

The Catapult was announced by the Chancellor of the Exchequer, George Osborne in July 2015. It will be located in the north-west of England at Alderley Park, recognising

Under the FDA’s rare pediatric disease priority review voucher program, the sponsor may be eligible for a voucher that can be used to obtain a priority review for

The consortium is developing a novel treatment for clotting disorders, targeting antithrombin III, a protein which inhibits blood clotting. Members will provide their know-how and expertise to produce

The company bought full rights to patents, compounds, know-how and collaboration/licence deals from Altermune for an undisclosed amount. Centauri will use the Alphamer technology for drug discovery and

A prescription drug user fee act action date of 16 May 2016 has been assigned, six months after the submission of the sNDA. The sNDA was based on

The contracts are for global clinical trials of novel drugs for Alzheimer’s disease which span the three major phases of drug development and are expected to run for

Shire agreed to purchase US-based Baxalta for $32bn after six months of hot pursuit. Shire reported that it has offered to pay $18 in cash and 0.1482 of